financetom
Business
financetom
/
Business
/
Why Is Lennar Corporation Stock Trading Higher Today?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Is Lennar Corporation Stock Trading Higher Today?
Mar 17, 2026 10:30 AM

Shares of Lennar Corporation ( LEN ) are trading higher Tuesday after several analysts adjusted their price targets on the stock.

Lennar ( LEN ) stock is showing downward pressure. What’s the outlook for LEN shares?

Analyst Adjust Ratings After Earnings Miss Last Week

Lennar’s quarterly earnings of $0.88 per share missed the analyst consensus estimate of $0.96 by 8.24 percent. The company reported quarterly sales of $6.619 billion which missed the analyst consensus estimate of $6.883 billion by 3.83 percent.

Evercore ISI Group analyst Stephen Kim maintained an underperform and lowered the price target from $92 to $91.

Wells Fargo analyst Sam Reid maintained an equal-weight and lowered the price target from $105 to $100.

Truist Securities analyst Jonathan Bettenhausen maintained a hold and lowered the price target from $110 to $95.

Barclays analyst Matthew Bouley maintained an underweight and lowered the price target from $88 to $85.

UBS analyst John Lovallo maintained a neutral and lowered the price target from $122 to $107.

Earnings Outlook

Looking further out, the next major catalyst for the stock arrives with the June 15, 2026 (estimated) earnings report.

EPS Estimate: $1.38 (Down from $1.90 YoY)

Revenue Estimate: $8.10 Billion (Down from $8.38 Billion YoY)

Valuation: P/E of 13.8x (Indicates value opportunity relative to peers)

Shares Slightly Up In Regular Trading

LEN Stock Price Activity: Lennar ( LEN ) shares were up 0.90% at $96.81 at the time of publication on Tuesday, according to Benzinga Pro data.

Image: Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Identiv Receives Final US Approval to Sell Security Card Business to Viaprotech
Identiv Receives Final US Approval to Sell Security Card Business to Viaprotech
Aug 19, 2024
08:25 AM EDT, 08/19/2024 (MT Newswires) -- Identiv ( INVE ) said Monday that it has received US regulatory approval to sell its security access card and reader operations to Turkey's Viaprotech for $145 million. The Committee on Foreign Investment in the US approved Identiv's ( INVE ) application on Aug. 15, the company said. The two companies expect the...
Canada's Couche-Tard confirms buyout offer for Japan's Seven & i
Canada's Couche-Tard confirms buyout offer for Japan's Seven & i
Aug 19, 2024
(Reuters) - Canada's Alimentation Couche-Tard ( ANCTF ) confirmed on Monday it has made an offer to buy Japan's Seven & i ( SVNDF ). The 7-Eleven owner had said earlier on Monday it had received a preliminary takeover offer from Couche-Tard and has formed a special committee to review the proposal. Shares of Seven & i ( SVNDF )...
Market Chatter: Uber Drivers in Kenya Reject App's Lower Fares, Collaborate to Raise Rates
Market Chatter: Uber Drivers in Kenya Reject App's Lower Fares, Collaborate to Raise Rates
Aug 19, 2024
08:21 AM EDT, 08/19/2024 (MT Newswires) -- Uber Technologies ( UBER ) drivers in Kenya are ignoring fares computed by the ride-hailing app and charging their own higher rates, Reuters reported, citing drivers in Nairobi. Drivers for Uber ( UBER ) and other ride-hailing apps message potential passengers and propose higher prices than those generated by the companies, Reuters said....
Monte Rosa Therapeutics Doses First Participants in MRT-6160 Autoimmune Study
Monte Rosa Therapeutics Doses First Participants in MRT-6160 Autoimmune Study
Aug 19, 2024
08:25 AM EDT, 08/19/2024 (MT Newswires) -- Monte Rosa Therapeutics ( GLUE ) said Monday it has dosed the first participants in a phase 1 trial evaluating MRT-6160, its experimental molecular glue degrader targeting VAV1 for autoimmune diseases. Initial results are due in Q1 2025, the company said. Monte Rosa said the study will assess the safety, pharmacokinetics, and target...
Copyright 2023-2026 - www.financetom.com All Rights Reserved